Fri, Jul 11, 2014, 6:22 AM EDT - U.S. Markets open in 3 hrs 8 mins

Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

  • dooper55 dooper55 Apr 19, 2013 8:00 AM Flag

    Spreading the word on OMS303

    OMER PR this morning. Not significant IMO, just presenting OMS302 info to a different audience.
    ******************************************************************************
    April 19, 2013, 7:00 a.m. ET.
    Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress

    SEATTLE, April 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302, at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress taking place in San Francisco April 19-23. The podium presentation, "Effect of an Anti-inflammatory-Mydriatic Agent on the Incidence of Intraoperative Miosis During IOL Replacement Surgery," summarizes key analyses of Phase 2 and Phase 3 clinical data assessing the ability of OMS302 to reduce the incidence of miosis (pupil constriction) during intraoperative lens replacement surgery. These analyses will be included in both the US and European marketing applications for OMS302. Steve Whitaker, M.D., Omeros' vice president of clinical development and chief medical officer, will present the data at 3:27 p.m. PDT on April 21 in the Intraocular Surgery/Medications Session.

    About Omeros' OMS302 Program

    OMS302 is Omeros' product being developed for use during intraocular lens replacement (ILR), including cataract surgery and refractive lens exchange. OMS302 is a proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac. Omeros recently completed its successful OMS302 Phase 3 clinical program and expects to submit a New Drug Application to the U.S. Food and Drug Administration this quarter and a Marketing Authorization Application to the European Medicines Agency in mid-2013.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • succhiacazzo@rocketmail.com succhiacazzo Apr 19, 2013 10:29 AM Flag

      So OMS302 is "proprietary combination of the mydriatic (pupil dilating) agent phenylephrine and the anti-inflammatory agent ketorolac." I was always taught to run away whenever a company starts talking about its "proprietary" anything and this looks like a good example.
      It's just a combination of two generic drugs that the pharmacist mixes with water and which the surgeon uses as an irrigating solution. Exactly how much is used in a typical surgery? It couldn't be much since IOL surgery doesn't require much irrigation. How much does OMER think it can make per surgery?
      Not only that, why would a surgeon even bother to request it. The eyedrops they currently use seem to do everything required.
      Like I said, "proprietary" is usually a bright red warning beacon meaning "stay away."

      Sentiment: Strong Sell

 
OMER
14.61-0.14(-0.95%)Jul 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.